External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home SNO 2020
Roche and Genentech at

SNO 2020

November 19 - November 22
Austin, USA
soc-neuro-onc.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
07:00 AM
Duration 5mins Virtual
Patient-reported outcomes following pertuzumab plus high-dose trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) and central nervous system (CNS) progression post-radiotherapy
Kumthekar P, Sahebjam S, Pegram M, Ibrahim N, Sussell J, Nicholas A, Fung A, Cheng A, Lin NU
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.